Androgênios e o trato reprodutor masculino: ações clássicas e perspectivas atuais by Patrão, Marilia T. C. C. et al.
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
Arq Bras Endocrinol Metab. 2009;53/8934
review
Androgens and the male reproductive 
tract: an overview of classical 
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ABSTRACT
Androgens are steroid hormones that play key roles in the development and maintenance of 
male phenotype and reproductive function. These hormones also affect the function of several 
non-reproductive organs, such as bone and skeletal muscle. Endogenous androgens exert most 
of their effects by genomic mechanisms, which involve hormone binding to the androgen recep-
tor (AR), a ligand-activated transcription factor, resulting in the modulation of gene expression. 
AR-induced non-genomic mechanisms have also been reported. A large number of steroidal 
and non-steroidal AR-ligands have been developed for therapeutic use, including the treatment 
of male hypogonadism (AR agonists) and prostate diseases (AR antagonists), among other pa-
thological conditions. Here, the AR gene and protein structure, mechanism of action and AR 
gene homologous regulation were reviewed. The AR expression pattern, its in vivo regulation 
and physiological relevance in the developing and adult testis and epididymis, which are sites 
of sperm production and maturation, respectively, were also presented. Arq Bras Endocrinol Metab. 
2009;53(8):934-45
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RESUMO
Os androgênios são hormônios esteroides com papel fundamental no desenvolvimento e na 
manutenção do fenótipo masculino e da função reprodutiva. Esses hormônios também afetam 
a função de diversos tecidos não reprodutivos, como, por exemplo, o ósseo e musculoesquelé-
tico. Os androgênios endógenos exercem a maioria de suas funções por mecanismo genômico, 
que envolve a ligação do hormônio ao receptor de androgênio (RA), um fator de transcrição 
ativado por ligante, o que resulta no controle da expressão gênica. Mecanismos não genômicos 
também têm sido associados aos efeitos induzidos pelo RA. Um grande número de ligantes do 
RA, esteroidais e não esteroidais, tem sido desenvolvido para o uso terapêutico, incluindo o tra-
tamento do hipogonadismo masculino (agonistas do RA) e de doenças da próstata (antagonis-
tas do RA), entre outras condições patológicas. Neste trabalho, foram discutidas as caracterís-
ticas estruturais básicas do RA (gene e proteína), os mecanismos de ação desse receptor, bem 
como aspectos relacionados à sua regulação homóloga. O padrão de expressão do RA, sua 
regulação in vivo e relevância fisiológica durante o desenvolvimento e a vida adulta na função 
do testículo e epidídimo, tecidos responsáveis pela produção e maturação de espermatozoides, 
respectivamente, também foram discutidos. Arq Bras Endocrinol Metab. 2009;53(8):934-45
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InTRODUCTIOn
Androgens are steroid hormones primarily involved in the development of male-specific phenotype 
during embryogenesis, in the establishment of sexual 
maturation at puberty, and in the maintenance of the 
male reproductive function, spermatogenesis and sexual 
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
935Arq Bras Endocrinol Metab. 2009;53/8
Androgens and the male reproductive tract
behavior during adult life. They also affect a wide va-
riety of functions in non-reproductive tissues, such as 
bone and skeletal muscle, on both male and female (for 
review, see  1).
Endogenous androgens, mainly testosterone and 
its active metabolite dihydrotestosterone (DHT), ex-
ert most of their effects by binding to the androgen 
receptor (AR), a ligand-activated transcription factor, 
which results in the control of gene transcription by the 
interaction of AR with coregulators and specific DNA 
sequences of androgen-responsive genes of the target 
cells. Recently, a number of rapid, non-genomic effects 
have also been associated with AR activation by andro-
gens, with physiological relevance to be still determined. 
Due to the involvement of androgens in a large number 
of pathological processes, several synthetic steroidal and 
non-steroidal AR ligands have been developed and are 
widely used in clinical applications, including the treat-
ment of male hypogonadism (AR agonists) and prostate 
diseases (AR antagonists), among others. 
In this review, the basic aspects of the AR gene and 
protein structure, the molecular mechanisms of andro-
gen action and the regulation of AR gene by androgens 
are presented. Aspects of the pattern of AR expression, 
its in vivo regulation during development and adult-
hood and its physiological relevance in the testis and 
the epididymis, which are sites of sperm production 
and maturation, respectively, are also briefly reviewed. 
AnDROgEn RECEpTOR gEnE AnD pROTEIn 
STRUCTURE 
The AR belongs to the nuclear hormone receptor su-
perfamily of ligand-activated transcription factors that 
also includes receptors for other mammalian steroid 
hormones, such as glucocorticoid receptor (GR), mi-
neralocorticoid receptor (MR), progesterone receptor 
(PR) and estrogen receptors (ERa and ERa). 
The human AR gene is located on X chromosome 
at position Xq11-q12 (2), spanning over 90-kilobase 
(kb) pairs that comprise eight exons, a large 5’-untrans-
lated region (5’-UTR, 1.1-kb in size) and a very large 
3’-untranslated region (3’-UTR, 6.8-kb in size) (3,4). 
Highly conserved human AR orthologs have been des-
cribed in different species, including mouse and rat (5-
7). All AR exons contribute to a transcript that encodes 
a modular protein of 919 amino acids with an apparent 
molecular mass of 110 kDa (6). Differential splicing 
in the 3’-UTR are known to produce two major AR 
mRNA species (11- and 8.5-kb, respectively) in diffe-
rent cell lines and tissues (3,6,8), with unknown phy-
siological function. At least three major transcription 
initiation sites, in an 18-base pair region located over 
1-kilobase upstream the ATG translation initiation co-
don, have been identified in the human AR gene (8), 
while only two of these sites are observed in the mou-
se and rat (5,9). Studies in different species, including 
human (10), mouse (5), rat (9) and hamster (11) have 
revealed that the promoter region of AR gene lacks ty-
pical TATA and CAAT sequence motifs in the 5’-UTR, 
two common motifs that are recognized by compo-
nents of the transcriptional machinery. It contains, ho-
wever, a CG-rich region that is an important cis-acting 
element for AR gene transcription and a putative site 
that binds the constitutive active transcription factor 
Sp1. Multiple consensus sequences that recognize di-
fferent transcription factors are also present in AR pro-
moter region of different species, including AR itself, 
GR, ER, activating protein-1 (AP-1), cAMP responsive 
binding element (CREB), among others (9,11,12).
Like other members of its family, the structure of 
AR is organized into functional domains, consisting 
of a N-terminal domain (NTD), encoded by exon 1; 
a DNA-binding domain (DBD), encoded by exons 
2 and 3; and a C-terminal ligand-binding domain 
(LBD), which is encoded by the last five exons (4). 
There is also a small hinge region between DBD and 
LBD. Whereas the DBD and LBD of the AR are highly 
conserved among species, the NTD display the most 
sequence variability, which is important for differences 
in the homeostatic control and complexity of AR signa-
ling (13). The AR NTD is relatively long, representing 
almost half of the receptor coding sequence; it contains 
the major transactivation function domain of the AR, 
termed activation function 1 (AF1), which is responsi-
ble for almost all AR transcriptional activity (14). Mu-
tagenesis and deletion studies have indicated that, in 
a construct corresponding to a truncated AR lacking 
the LBD, the AF1 becomes constitutively transcriptio-
nal active (14). Additionally, AF1 mediates interactions 
with transcriptional coregulators and members of the 
basal transcriptional machinery (for review, see 15). 
The AR NTD also contains motifs that interact with 
LBD after agonist binding, resulting in an amino-/car-
boxi-terminal intra- and/or intermolecular interaction, 
named N/C interaction, which may be critical for the 
transcriptional activation of some AR target genes (for 
review, see 16).  
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The cystein-rich DBD is the most conserved region 
within the nuclear receptor family, with identical ami-
no acid sequence when AR DBD from human, rat and 
mouse are compared (5,6). This domain contains two 
zinc finger motifs and a C-terminal extension. The first 
zinc finger mediates specific DNA recognition, whe-
reas the second is involved in AR homodimerization 
and DNA/receptor complex stabilization (17). The 
C-terminal region of DBD and the hinge region con-
tain ligand-dependent bipartite nuclear localization sig-
nals (NLS), indicating the role of these regions on AR 
translocation to the cell nucleus (18).
The LBD mediates high affinity interactions betwe-
en AR and its steroidal and non-steroidal ligands. It 
is also important for AR interactions with chaperones 
(19). The three-dimensional structure of this domain 
was described early this decade (20). Similar to other 
steroid hormone receptors, the AR LBD consists of 
12 a-helices that form a ligand-binding pocket. Upon 
agonist binding, there is a conformational change in 
LBD, resulting in the stabilization of helix 12 and the 
formation of a functional activation function 2 (AF2) 
on the surface of this domain. AF2 plays a pivotal role 
on intra- and intermolecular N/C interactions, which 
may further stabilize AR-bound androgen complex and 
play a role on receptor dimerization (16,21). The LBD 
is also involved in the recruitment of coregulators du-
ring transcriptional activation. Nevertheless, N/C in-
teractions usually impair the access of coregulators to 
AF2, which may explain why AF1 is the major transac-
tivation region of the AR, a phenomenon not observed 
with ER and GR, for example (16). Although AR AF2 
ligand-dependent transactivation activity is weak when 
compared with similar domains from other steroid hor-
mone receptors, its importance for AR function was 
demonstrated by discrete reductions on its transcrip-
tional activity in response to ligand after mutations or 
deletion of AF2 region (16). 
MOlECUlAR MEChAnISMS Of AnDROgEn 
ACTIOn
The classic genomic actions of androgens are based on 
the AR-mediated control of gene transcription. This 
mechanism usually requires at least 30 to 40 minutes to 
alter gene expression and hours to produce significant 
levels of newly expressed proteins. In the target cell, tes-
tosterone diffuses through the plasma membrane and 
interacts with AR trapped in the cytoplasm by a mul-
tiprotein complex with heat shock proteins (HSP) and 
immunophilin chaperones, including HSP90, HSP70, 
HSP56 and p23 (19). After ligand binding, AR under-
goes a conformational change, allowing its release from 
the multiprotein complex. This dissociation unmasks 
AR NLS and dimerization motifs, allowing its increa-
sed phosphorylation, nuclear translocation and homo-
dimerization. In the nucleus, activated AR-ligand ho-
modimer complex binds to specific recognition DNA 
sequences, the androgen response elements (AREs), lo-
calized in the promoter regions of androgen-regulated 
genes. The presence of functional AREs in enhancer 
intronic regions of AR-regulated genes has been also 
reported (22). 
Studies with recombinant human AR demonstrated 
that homodimerization is critical for DNA binding (23). 
The consensus ARE sequence has been identified as a 
partial palindromic 15-base pair element comprised of 
two imperfect 6-base pair indirect repeats with a 3-base 
pair space (5’-GG(A/T)ACANNNTGTTCT-3’) (for 
review, see 24). After binding to ARE, AR-ligand ho-
modimer complex can either directly interacts with 
components of the general transcriptional complex 
or recruits other components, such as transcriptional 
factors or coregulator proteins that act as a functional 
link between the transcriptional machinery and the 
AR-mediated transcriptional activity (for review, see 
19). AR coregulators can be defined as proteins that 
are recruited by the AR and either enhance (coactiva-
tors) or reduce (corepressors) its transcriptional activi-
ty, but lack intrinsic DNA binding capacity and do not 
change basal transcription rate in the absence of AR. 
Coregulators modulate AR-mediated transactivation 
at the target gene promoter region by several mecha-
nisms, including direct enhancement of AR to control 
gene transcription rate, modulation of DNA binding, 
chromatin remodeling, and recruitment of other fac-
tors associated with RNA polymerase II. According to 
the Nuclear Receptor Signaling Atlas (NURSA) data-
base (http://www.nursa.org), over 250 nuclear recep-
tor coregulator proteins have been identified. Many 
of them interact with AR and regulate its activity, in-
cluding steroid receptor coactivator 1 (SCR-1) (25), 
AR-associated protein 70 (ARA 70) (26), melanoma 
antigen gene product (MAGE-11) (27), among others 
(see Heemers and Tindall (19), for a comprehensive 
review). It is also known that AR further regulates gene 
expression by physical or functional interactions with 
transcription factors that bind to specific consensus se-
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quences, such as AP-1 (28), SRY and DAX1 (29). An-
drogens may also indirectly influence the expression of 
genes that do not necessarily contain canonical AREs 
in their promoter regions, involving modulation in the 
expression or activity of secondary transcription factors, 
the production of growth factors acting in an autocri-
ne or paracrine fashion or changes in the expression 
of other hormones. The development of selective an-
drogen receptor modulators (SARMs) that potentially 
regulate aspects of tissue-specific AR activation, such 
as ligand-induced receptor conformational changes, 
protein-protein interactions, and protein-DNA interac-
tions, has been highly explored due to their potential 
therapeutic applications as target for male contracep-
tion and their use in different clinical conditions, such 
as prostate cancer, benign prostatic hyperplasia, osteo-
porosis, among others (for review, see 30).
There are growing evidences indicating that andro-
gens are also able to trigger cellular processes through 
rapid, non-genomic mechanisms in different isolated 
cells and tissues, including testis and prostate (for re-
view, see 31). These non-genomic actions usually occur 
in seconds or minutes, not long enough to allow gene 
transcription and translation. It is often dependent on 
plasma membrane-associated signaling pathways that 
will lead to the activation of cytoplasmic second mes-
sengers, a mechanism that is not sensitive to transcrip-
tional or translational inhibitors. The most common 
non-genomic actions of androgens involve either rapid 
activation of kinase-associated intracellular signaling, 
including mitogen-activated protein kinase (MAPK) 
and protein kinase A (PKA) pathways, or the modula-
tion of intracellular calcium levels. The molecular me-
chanisms underlying these actions and their physiologi-
cal relevance remain largely unknown.
It has been also suggested that non-genomic me-
chanisms may be involved on the effects of androgens 
in the male reproductive tract. In fact, a rapid increase 
in the intracellular calcium concentration was observed 
when primary rat Sertoli cells and human androgen-de-
pendent (LNCaP) and androgen-independent (PC3) 
human prostate cancer cells were exposed to testoste-
rone, DHT and R1881 – a synthetic AR agonist (32). 
Similar results were obtained when these cells were sti-
mulated with a membrane-impermeable androgen ana-
logue (testosterone-conjugated to bovine serum albu-
min, T-BSA) (32). Furthermore, testosterone was able 
to induce a rapid increase on the concentration of the 
transcriptional factor CREB in rat primary Sertoli cell 
culture, via MAPK pathways, an effect impaired either 
by the knockdown of Ar gene expression by siRNA or 
by incubation of the cells with an AR antagonist (fluta-
mide), providing evidence that classical AR is required 
to initiate this non-genomic actions of testosterone in 
Sertoli cells (33). However, not all androgen-mediated 
non-genomic effects are blocked by the classical AR an-
tagonists (for review, see 31). It is also important to cite 
that there are evidences that isolated rat Sertoli cells and 
LNCaP cells contain a population of plasma membrane 
associated AR, which can be transiently increased in res-
ponse to testosterone stimulation (32). Thus, whether 
non-genomic actions in the male reproductive tract are 
mediated by classical AR, by a membrane-bound AR 
or by another membrane-associated signaling pathway 
and its potential actions in other reproductive tissues 
still require further investigation. 
MEChAnISMS Of hOMOlOgOUS REgUlATIOn  
Of AnDROgEn RECEpTOR
The regulation of AR expression by androgens is an 
important mechanism to self-regulate cell or tissue an-
drogen responsiveness. This homologous regulation is 
a complex time-, cell- and tissue-dependent event that 
involves the combination of transcriptional and post-
transcriptional mechanisms. In fact, androgens can 
autoregulate the expression of AR transcript in both 
negative and positive directions, according to the cell-
type analyzed. Northern blot studies conducted with 
LNCaP cells indicated that testosterone and DHT, as 
well as synthetic androgen agonists (R1881 and mibo-
lerone), down-regulate AR mRNA levels in these cells 
in a concentration- and time-dependent pattern (8,34, 
35), an effect caused by a predominant suppression of 
AR transcription associated with a paradoxical increase 
in AR mRNA half-life (from 5.5 hours in the absence 
of androgen to over 12 hours in the presence of 10 nM 
DHT) (8,35). A similar reduction of the AR mRNA 
levels after androgen treatment was observed in human 
breast cancer cell lines T47D and MDA453 (34,35) – 
in this case, as a consequence of post-transcriptional 
reduction on AR mRNA half-life (35), suggesting the 
existence of cell-type specific mechanisms involved in 
the regulation of AR mRNA expression. In a marked 
contrast, DHT increased AR mRNA steady-state levels 
in human osteoblastic cell lines (SaOS-2 and U2OS) 
that constitutively express AR, an effect induced by an 
increase in AR promoter activity, which depends on AR 
Androgens and the male reproductive tract
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transactivation mechanisms (36). Interestingly, studies 
conducted with monkey kidney COS-1 cells (37) and 
androgen independent cell lines PC3 and DU145 (38), 
all transiently transfected with human AR cDNA and 
stimulated with R1881, have indicated the presence of 
regulatory regions within the AR coding sequence that 
are important in AR gene homologous regulation. In 
fact, studies using PC3 cells transiently transfected with 
human AR cDNA have confirmed the presence of func-
tional AREs in exons 4 and 5 of AR gene (39).
Androgens can also up regulate the AR levels by 
promoting protein stabilization. In fact, degradation 
rate studies conducted in monkey kidney COS-1 cells 
transfected with AR cDNA demonstrated that, in the 
absence of androgen, the AR half-life is approximately 1 
to 1.5 hour at 37 oC (40,41). After androgen exposure, 
the AR half-life significantly increases in a concentration-
dependent manner (10 to 11 hours in the presence of 
10 nM DHT and over 14 hours in the presence of 100 
nM DHT) (40,41). This effect also directly depends on 
the androgen dissociation rates, since testosterone was 
less effective at increasing AR half-life than similar con-
centrations of DHT and R1881, which are agonists with 
higher affinity to AR (41). Higher degradation rates of 
an AR with a natural mutation in the LBD (valine-889 
conversion to methionine), a receptor presenting an in-
creased androgen dissociation rate when compared to 
AR-wild type in the presence of similar concentration 
of androgens, further indicate the importance of andro-
gen binding for AR stabilization (41). Besides, agonist-
induced AR stabilization is highly androgen-specific, 
since treatment with non-androgenic steroids failed to 
increase AR half-life (40). Analysis of AR deletion mu-
tants and AR/GR chimeras clearly demonstrate that AR 
NTD and LBD, but not DBD, play an important role 
on receptor stabilization after androgen binding (41). 
Indeed, N/C interaction induced by ligand binding is 
associated with AR stabilization (16). 
Although androgens are recognized as the main 
modulators of the development and maintenance of the 
male phenotype and reproductive function, the exact 
molecular mechanisms underlying in vivo homologous 
regulation of AR and its mechanism of action are still 
poorly understood in reproductive tissues, since most 
studies concerning these aspects are mainly based on 
in vitro cell lines (8,34,35,38). In this aspect, a better 
comprehension of the differential regulatory aspects of 
in vivo AR expression and its regulation is useful to fur-
ther understand the exact physiological roles of andro-
gens, as well as other steroid and non-steroid AR ligan-
ds, in the male reproductive tract and in the acquisition 
of a fertile ejaculate. Next, special focus will be given 
on the aspects regarding the pattern of AR expression 
and regulation by androgens, as well as its physiological 
relevance in the testis and epididymis during develop-
ment and adult life.
ExpRESSIOn AnD phySIOlOgICAl ROlES Of 
AnDROgEn RECEpTOR In ThE TESTIS AnD 
EpIDIDyMIS
fetal testis and Wolffian ducts
Androgens are responsible for the development of the 
male phenotype during embryogenesis. They are invol-
ved in testicular development, stabilization of the Wol-
ffian duct and its differentiation into epididymis, vas de-
ferens, seminal vesicle and ejaculatory duct, as well as in 
the differentiation of the prostate and external genitalia 
(for review, see 42, 43). Testosterone is produced by 
fetal Leydig cells at the eighth week of gestation in hu-
mans and at embryonic days 13 and 15 in mice and rats, 
respectively (43). In male rat fetuses (embryonic days 15 
to 19), AR is expressed earlier and more prominently in 
the interstitial cells surrounding testicular cords, inclu-
ding Leydig cells, in response to testosterone secretion 
(44,45). On the other hand, AR-positive Sertoli cells are 
not detected until postnatal day 5 in rats and postnatal 
days 4-9 in mice and their number, as well as AR immu-
nostaining intensity, increases over time (44,45). Thus, 
testosterone up regulates the expression of AR in the 
Leydig cells, but is not likely to be directly involved with 
Sertoli cell functions during fetal life (44,45).
Testosterone produced by embryonic Leydig cells 
reaches the Wolffian duct in two ways: (A) by the circu-
lation (endocrine interaction) and (B) by the testicular 
fluid (lumicrine interaction). Lumicrine interaction in-
volves testosterone reaching the Wolffian duct by the 
luminal compartment and is thought to be the main 
mechanism involved in Wolffian duct stabilization in the 
male fetus (for review, see 43). It is suggested that tes-
tosterone reaches the Wolffian duct bound to androgen 
binding protein (ABP), indicating that this protein may 
be important to the maintenance of high androgen le-
vels in the proximal region of the duct when compared 
to the remaining tissue (46). In the rat, the Wolffian 
duct first expresses AR in the mesenchymal cells at em-
bryonic day 14-15 and subsequently in the epithelial 
Androgens and the male reproductive tract
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
939Arq Bras Endocrinol Metab. 2009;53/8
cells (44,47). Testosterone reaching the Wolffian duct 
by the luminal compartment up regulates AR levels and 
induces proliferation of the epithelial cells through me-
senchymal-epithelial cell interactions involving paracri-
ne factors (48). At this stage, growth factors and com-
ponents of the extracellular matrix are proposed to be 
important mediators from the mesenchyme to the epi-
thelium (49). Recently, it has been suggested that circu-
lating androgens are also important to induce Wolffian 
duct stabilization and subsequent formation of epidi-
dymides, as well as prostatic bud formation, virilization 
of the urogenital sinus and prostatic development (50).
It is known that steroid hormones and growth fac-
tors are involved in the complex regulation of cell pro-
liferation and differentiation during pre- and postnatal 
development of the male reproductive tract (for review, 
see 43). Microarray analysis of the genes differentially 
expressed in the Wolffian ducts of male rat fetuses from 
mothers treated with the weak anti-androgen linurion, 
from days 12 to 21 of pregnancy, has demonstrated 
significant changes in mRNA expression of insulin-like 
growth factor 1 (IGF-1), bone morphogenetic protein 
(BMP), fibroblast growth factor (FGF) and epidermal 
growth factor (EGF) signaling pathways, consistent 
with a disruption of paracrine interactions between me-
senchymal and epithelial cells in the testosterone-me-
diated development of the Wolffian duct. A significant 
decrease in Ar transcript levels in the Wolffian duct at 
embryonic day 21 is also observed in this experimental 
model, confirming that Ar mRNA expression is indu-
ced by androgens in this structure (51). 
Adult testis and epididymis
In the adult male mouse and rat testes, AR is detected 
predominantly in the nuclear region of Sertoli, peritubu-
lar myoid, Leydig and perivascular smooth muscle cells 
(52-54), presenting a stage-specific pattern of immunos-
taining (53,54). The presence of AR in the germ cells 
and spermatozoa, however, is controversial and seems 
to depend on the species analyzed (for review, see 55). 
The fact that Sertoli cells AR conditional knockout mice 
are infertile, whereas germ cell conditional AR knockout 
mice are fertile, suggests that the role of AR on sperma-
togenesis is indirect and occurs via Sertoli cells (55). On 
the other hand, immunofluorescence, Western blot and 
functional assays have revealed that human ejaculated 
sperm expresses a functional AR in its head region, since 
changes in phosphoinositide-3 kinase/protein kinase B 
(PI3K/AKT) signaling pathway by a non-genomic me-
chanism were observed after incubation of these cells 
with DHT (56). However, the role of androgens in the 
maturing sperm is still unknown, since no information 
is available about the expression and function of AR in 
these cells during their transport throughout the epidi-
dymis, an organ from the male reproductive tract invol-
ved in the maturation, transport, protection and storage 
of spermatozoa prior to ejaculation (for review, see 57). 
The epididymis is constituted by a single, highly 
convoluted tubule, which connects the efferent ductu-
les to the vas deferens. Based on its morphological and 
histological characteristics, this tissue can be divided 
into different regions (initial segment, caput, corpus 
and cauda) depending on the species analyzed. The epi-
thelium of the epididymis contains different cell types: 
principal, basal, clear, narrow and halo cells (for review, 
see 57). Lumicrine interaction between androgens and 
AR involves transport of testosterone bound to ABP 
from the testis to the proximal region of the epididy-
mis. Testosterone/ABP complexes are then taken up to 
the cytoplasm of the epithelial cells, where 5a-reducta-
se enzyme converts this hormone into DHT, the main 
androgen regulating epididymal function (58). In the 
adult rat, ABP is localized in granules in the apical cyto-
plasm of the epithelial cells from initial segment and 
proximal caput, but not from distal caput, corpus and 
cauda epididymis (59), indicating its importance on the 
maintenance of high androgen levels in the proximal 
epididymis when compared to the remaining tissue 
(59). In fact, it is known that androgen concentrations 
are higher in the caput than in cauda epididymis (60) 
and that during postnatal development, which occurs 
from day 0 to day 44 after birth in rats, histological di-
fferentiation of the caput precedes that of the cauda (for 
review, see 57). Besides, the abundance of AR-positive 
cells in the epididymis increases in a time-dependent 
manner during postnatal development, which further 
confirms the involvement of this receptor in the normal 
epididymal development (44). In the adult rat and hu-
man epididymis, AR is present predominantly in the nu-
clear region of epithelial, interstitial and smooth muscle 
cells lining epididymal tubules and blood vessels (52, 
61) and also in the cytoplasm of epithelial cells (54,61). 
The AR distribution pattern in the different regions of 
the adult rat epididymis can be seen in figure 1. 
Surgical castration has been a useful tool to unders-
tand the roles of luminal and circulating androgens on 
AR function (58). This procedure induces a wave of 
apoptotic cell death in the epididymis, which occurs 
Androgens and the male reproductive tract
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progressively from the proximal to the distal region of 
this tissue (62). After surgical castration, a decrease in 
epididymal weight, luminal diameter and epithelial cell 
height, as well as a relative increase in the interstitial com-
partment are observed (for review, see 57). The secre-
tory and absorptive function of epithelial cells becomes 
compromised, which is accompanied by the loss of apical 
microvilli from their surface, lysosome accumulation, va-
cuolization, disappearance of vesicles from the cell apex, 
and increased endocytosis (for review, see 57). Testoste-
rone replacement to castrated rats restores most of the 
histological features of the epithelium, except in the ini-
tial segment, due to its high dependence on other non-
hormonal testicular factors (63,64). In fact, testosterone 
replacement to castrated rats triggers cell proliferation 
in a segment-specific and time-dependent manner, with 
corpus and cauda being the most affected regions (64).
As a result of the differential regulation by androgens 
and other hormonal and non-hormonal factors, epi-
didymal gene expression is segmentally regulated (51). 
In fact, the control of gene transcription by androgens 
varies along the epididymis and is differentially affected 
with progression of surgical castration (65). Microarray 
analysis of 474 genes was used to evaluate gene expres-
sion changes over the first seven days postsurgical castra-
tion in the initial segment, caput, corpus, and cauda epi-
didymis from adult rats. Several genes encoding proteins 
involved in cell viability and metabolism, as well as sperm 
maturation, were shown to be androgen-regulated (65). 
Microarray analysis of 31,000 genes indicated that, of the 
1,059 genes that were affected by surgical castration after 
seven days, DHT treatment for seven consecutive days 
was capable of restoring over 75% of the gene levels to-
ward the control, indicating that testosterone and DHT 
may differentially regulate the relative levels of such gene 
transcripts along rat epididymis (58). Data from our la-
boratory further confirm that differential regulation by 
androgens can also occur in the expression of genes en-
coding G-protein coupled receptors along rat epididymis, 
such as a1-adrenoceptor (66) and acetylcholine musca-
rinic receptor (67), which are receptors involved in the 
autonomic regulation of epididymal function (for review, 
see 68).
hOMOlOgOUS REgUlATIOn Of AnDROgEn 
RECEpTOR In ADUlT TESTIS AnD EpIDIDyMIS
In the testis from adult males, androgen withdrawal in-
duces AR cellular redistribution and up regulates AR 
figure 1. Immunolocalization of AR in the initial segment, caput and cauda 
epididymis from adult Wistar rats (90 days of age). Immunohistochemistry was 
conducted in our laboratory with cryosections (8 µm), as described by Queiróz and 
cols. (74), with an affinity purified rabbit polyclonal antibody raised against a peptide 
mapping at the N-terminus of AR of human origin, which also recognizes rat AR 
(1:500, Sc-816, Santa Cruz Biotechnology). Negative controls were performed with 
primary antibody previously incubated with its respective blocking peptide from 
Santa Cruz (inserts). Sections were counterstained with methylene blue. The different 
epididymal compartments lumen (Lu), epithelium (Ep), interstitium (Is) and smooth 
muscle layer (Mu) are indicated. Results are representative of experiments performed 
with tissues from four rats. Arrow: AR-positive nuclear staining. A faint diffuse and 
punctate immunostaining can also be observed in the cytoplasm of epithelial cells in 
all epididymal regions analyzed. Scale bar: 50 µm.
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ber of AR binding sites in the caput epididymis, whe-
reas bilateral surgical castration up to 20 days results in 
a decrease on AR binding sites, which points out for 
the importance of circulating rather than luminal an-
drogens on the regulation of AR expression (70). The 
Ar mRNA levels in the initial segment from adult rats 
submitted to EDL for 24 hours did not differ from 
sham-operated rats, confirming the low dependence of 
AR expression by luminal androgens (71). Immunohis-
tochemical studies demonstrated that bilateral surgical 
castration down regulates AR expression in the goat epi-
didymis, an effect reversed by testosterone replacement. 
In this experimental model, neither unilateral ligation 
of the rete testis nor unilateral surgical castration had 
any effect on AR expression (72). As shown in figure 2, 
our laboratory has evidences of an up regulation of Ar 
figure 2. Effects of the manipulation of androgen plasma levels on AR expression in epididymis from adult Wistar rats (90 days of age). Caput (including initial segment) and 
cauda epididymis were obtained from control, surgical castrated (CA, 7 and 15 days) and 7-day CA rats treated with testosterone propionate (7-day CA + T, 10 mg/kg, s.c., 
daily injections for six days). (A) Detection of Ar mRNA by RT-PCR in caput and cauda epididymis from the different experimental groups, as indicated. The 600 base pair band 
correspondent to Ar transcript is indicated (right arrow). (B) Densitometric analysis of the RT-PCR results. Each sample was normalized to its respective internal standard 
(Gapdh). (C) AR detection by Western blot analysis using caput and cauda epididymis total protein extracts from the different experimental groups, as indicated. Experiments 
were performed with an anti-AR antibody (1:600, Sc-816, Santa Cruz Biotechnology). Negative controls were performed with primary antibody previously incubated with its 
blocking peptide (data not shown). The 110 kDa band correspondent to the full length AR is indicated (right arrow). (D) Densitometric analysis of the Western blot results. Each 
sample was normalized to its respective internal standard (actin). Results are representative of experiments performed with tissues from four to five rats. Each bar and vertical 
line represent the normalized data expressed as percentage of control group (mean ± SEM). RT-PCR and Western blot studies were performed as described by Rodrigues and 
cols. (75). * p < 0.05 when compared with control group; # p < 0.05 when compared with 7-day CA + T group.
levels. Adult rats treated with ethane dimethane sul-
phonate (EDS), to eliminate the Leydig cells, presented 
low binding of 3H-R1881 to AR in the nuclear fraction 
of testicular cells when compared to controls (69). The 
total testicular AR was close to control levels, indica-
ting that in the absence of androgens, AR is redistribu-
ted to the cytoplasm of such cells (69). On the other 
hand, immunohistochemical studies have revealed that 
treatment of adult male mice with the GnRH antago-
nist azaline B, used to suppress LH and testosterone 
production, induces down-regulation of the receptor in 
the Leydig, peritubular and Sertoli cells (54). 
Regarding the homologous regulation of AR ex-
pression in the epididymis, radioligand binding studies 
demonstrated that bilateral efferent ductules ligation 
(EDL) for seven days does not affect the relative num-
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figure 3. Effects of the manipulation of androgen plasma levels on AR cellular distribution in epididymis from adult Wistar rats (90 days of age). Immunolocalization of AR using 
cryosections (8 µm) from caput (A) and cauda epididymis (B) from control, surgical castrated (CA, 7 and 15 days) and 7-day CA rats treated with testosterone propionate (7-day 
CA + T, 10 mg/kg, s.c., daily injections for six days) is shown. Experiments were performed as described by Queiróz and cols. (74), using an anti-AR antibody (1:500, Sc-816, 
Santa Cruz Biotechnology). Negative controls were performed with primary antibody previously incubated with its respective blocking peptide from Santa Cruz (data not shown). 
Sections were counterstained with methylene blue. The different epididymal compartments lumen (Lu), epithelium (Ep), interstitium (Is) and smooth muscle layer (Mu) are 
indicated. Results are representative of experiments performed with tissues from four to five rats. Arrow: AR-positive nuclear staining. Scale bar: 50 µm.
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mRNA levels with a concomitant down regulation of 
AR protein levels, that occur in both caput and cauda 
epididymis of adult rats submitted to bilateral surgical 
castration for 7- and 15-days, suggesting the existence 
of differential mechanisms of AR regulation at mRNA 
and protein levels by endogenous androgens in the rat 
epididymis, as also described in studies performed with 
cell lines (8,34,35,40,41). Our immunohistochemistry, 
using epididymal cryosections from the same animals, 
indicated a significant reduction on AR-positive nu-
clear staining in epithelial cells from caput and cauda 
epididymis after castration (Figure 3). Remarkably, no 
AR-positive immunostaining was observed in interstitial 
and smooth muscle cells of caput epididymis from cas-
trated rats, further indicating the existence of different 
regulatory mechanisms of AR expression between the 
epididymal cells (Figure 3). In fact, immunohistochemi-
cal studies performed with epididymis from chemically 
castrated rats treated with azaline B also demonstrate 
a time-dependent reduction on AR-positive nuclear 
staining, observed earlier in interstitial than in epithe-
lial epididymal cells (54). Testosterone replacement (10 
mg/kg, s.c., daily injections during six days) for 7-day 
castrated rats was able to restore AR expression, at both 
mRNA and protein levels in caput and cauda epididy-
mis, reinforcing the importance of circulating andro-
gens on such regulation (Figures 2 and 3). Similar re-
sults were obtained when immunohistochemical studies 
were performed with the epididymis from rats treated 
with the 5a-reductase inhibitor finasteride that inhibits 
the conversion of testosterone into DHT (73).
COnClUDIng REMARKS 
New information has been obtained in the last decade 
in relation to the mechanism of action of androgens, 
which is known to involve genomic, and also non-ge-
nomic signaling pathways induced by AR. However, 
further investigation is still required to fully understand 
how these events collectively contribute to AR physio-
logical function in the male reproductive tract, espe-
cially to testis and epididymis, tissues highly involved 
in the achievement of male fertility. It is hoped that 
information on selective AR modulators (SARMs) and 
AR coregulator proteins, that potentially regulate as-
pects of tissue-specific AR activation, will serve as tools 
to be used not only for more efficient pharmacological 
modulation of the AR in pathological processes, such 
as certain conditions of male hypogonadism, diseases of 
the prostate and osteoporosis, as well as for the deve-
lopment of therapies for male contraception and treat-
ment of male infertility.
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